← Leaderboards
David S Newburg
Eastern Virginia Medical School
$14,172,006
Attributed
$14,172,006
Total exposure
20
Grants
13
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2.3M · FY2005–14$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
Funding mix
By agency
NIH$14,172,006 · 20
By mechanism
U01$4,506,555 · 1
R01$4,399,155 · 3
P01$3,833,131 · 6
P30$1,108,453 · 1
P41$324,712 · 9
Top collaborators
No co-investigators on record.
Most similar at Eastern Virginia Medical School
Same institution · by research overlap
- Jenn A Leiferman$4,672,631
Others in their field
Top investigators on “Oligosaccharides”
- Dennis L. Kasper · Harvard Medical School$27,868,053
- Geert-Jan Boons · University Of Georgia (Uga)$16,473,058
- Jacques U Baenziger · Washington University$12,267,027
- Jian None Liu · University Of North Carolina Chapel Hill$11,679,776
- Ajit P Varki · University Of California San Diego$11,487,386
- Wayne Lencer · Children'S Hospital Boston$11,480,415
Research focus
OligosaccharidesPolysaccharidesHuman MilkPathogenGlycolipidsCell SurfaceGlycoconjugatesInfectionStructureDesignConsumptionMolecularCellsLipidsIntestinal MucosaBinding (Molecular Function)Signal TransductionComplexMacrophageIntestinesLymphocyteInfantBreast FeedingEscherichia Coli
Grant awards (54)
Oligosaccharide moieties of human milk glycans that inhibit pathogens$582,970
R01 · FY2014 · HD · contact PI
Oligosaccharide moieties of human milk glycans that inhibit pathogens$553,971
R01 · FY2013 · HD · contact PI
Intestinal Mucosa Project$241,642
P01 · FY2013 · HD · contact PI
Glycobiology Core$207,229
P01 · FY2013 · HD · contact PI
Oligosaccharide moieties of human milk glycans that inhibit pathogens$567,329
R01 · FY2012 · HD · contact PI
Intestinal Mucosa Project$248,645
P01 · FY2012 · HD · contact PI
Glycobiology Core$219,856
P01 · FY2012 · HD · contact PI
Novel broad spectrum therapeutic glycans against Category B pathogens$890,257
U01 · FY2011 · AI · contact PI
Intestinal Mucosa Project$246,734
P01 · FY2011 · HD · contact PI
Glycobiology Core$226,034
P01 · FY2011 · HD · contact PI
CHARACTERIZATION OF SULFATIDES AND GAGS IN HUMAN MILK$99,317
P41 · FY2011 · RR · contact PI
Novel broad spectrum therapeutic glycans against Category B pathogens$899,251
U01 · FY2010 · AI · contact PI
Oligosaccharide moieties of human milk glycans that inhibit pathogens$601,507
R01 · FY2010 · HD · contact PI
CORE--Cell Biology$281,670
P30 · FY2010 · DK · contact PI
Intestinal Mucosa Project$219,246
P01 · FY2010 · HD · contact PI
Glycobiology Core$202,632
P01 · FY2010 · HD · contact PI
CHARACTERIZATION OF SULFATIDES AND OTHER LIPID CONJUGATES IN HUMAN MILK$31,040
P41 · FY2010 · RR · contact PI
Novel broad spectrum therapeutic glycans against Category B pathogens$961,998
U01 · FY2009 · AI · contact PI
Oligosaccharide moieties of human milk glycans that inhibit pathogens$654,000
R01 · FY2009 · HD · contact PI
CORE--Cell Biology$237,466
P30 · FY2009 · DK · contact PI
Intestinal Mucosa Project$226,942
P01 · FY2009 · HD · contact PI
Glycobiology Core$210,635
P01 · FY2009 · HD · contact PI
CHARACTERIZATION OF SULFATIDES AND OTHER LIPID CONJUGATES IN HUMAN MILK: HIV$30,136
P41 · FY2009 · RR · contact PI
Novel broad spectrum therapeutic glycans against Category B pathogens$858,575
U01 · FY2008 · AI · contact PI
CORE--Cell Biology$238,127
P30 · FY2008 · DK · contact PI
CHARACTERIZATION OF SULFATIDES AND OTHER LIPID CONJUGATES IN HUMAN MILK: HIV$7,067
P41 · FY2008 · RR · contact PI
Novel broad spectrum therapeutic glycans against Category B pathogens$896,474
U01 · FY2007 · AI · contact PI
Glycobiology Core$171,423
P01 · FY2007 · HD · contact PI
CORE--Cell Biology$167,701
P30 · FY2007 · DK · contact PI
Stable Toxin Project$107,137
P01 · FY2007 · HD · contact PI
CHARACTERIZATION OF SULFATIDES AND OTHER LIPID CONJUGATES IN HUMAN MILK: HIV$25,054
P41 · FY2007 · RR · contact PI
CORE--Cell Biology$183,489
P30 · FY2006 · DK · contact PI
ANTI-INFLAMMATORY FACTOR IN SACCHAROMYCES BOULARDI$2,558
P41 · FY2006 · RR · contact PI
ANTI-INFLAMMATORY FACTOR IN SACCHAROMYCES BOULARDI$2,551
P41 · FY2005 · RR
ENDOTHELIAL GB3 SPECIES INVOLVED IN HUS PATHOGENESIS$276,023
R01 · FY2003 · DK
ENDOTHELIAL GB3 SPECIES INVOLVED IN HUS PATHOGENESIS$300,233
R01 · FY2002 · DK
CORE--BIOCHEMISTRY$172,411
P01 · FY2002 · HD
ESCHERICHIA COLI STABLE ENTEROTOXIN$172,411
P01 · FY2002 · HD
HOST CELLULAR RECEPTORS AND HUS$210,922
R01 · FY2001 · DK
ESCHERICHIA COLI STABLE ENTEROTOXIN$176,415
P01 · FY2001 · HD
CORE--BIOCHEMISTRY$176,415
P01 · FY2001 · HD
Endothelial Gb3 Species Involved in HUS Pathogenesis$174,375
R01 · FY2001 · DK
ESCHERICHIA COLI STABLE ENTEROTOXIN$172,411
P01 · FY2001 · HD
CORE--BIOCHEMISTRY$172,411
P01 · FY2001 · HD
ENDOTHELIAL GB3 SPECIES INVOLVED IN HUS PATHOGENESIS$136,523
R01 · FY2001 · DK
HUMAN MILK IN INFANT NUTRITION &HEALTH$53,566
P41 · FY2001 · RR
HOST CELLULAR RECEPTORS &HUS HPLC BASED METHOD FOR GLOBOSIDE GB3 ANALYSIS$53,566
P41 · FY2001 · RR
ENDOTHELIAL GB3 SPECIES INVOLVED IN HUS PATHOGENESIS$136,523
R01 · FY2000 · DK
CORE--BIOCHEMISTRY$131,251
P01 · FY2000 · HD
ESCHERICHIA COLI STABLE ENTEROTOXIN$131,251
P01 · FY2000 · HD
HOST CELLULAR RECEPTORS AND HUS$102,390
R01 · FY2000 · DK
HOST CELLULAR RECEPTORS AND HUS$102,389
R01 · FY2000 · DK
HOST CELLULAR RECEPTORS &HUS HPLC BASED METHOD FOR GLOBOSIDE GB3 ANALYSIS$13,658
P41 · FY2000 · RR
HUMAN MILK IN INFANT NUTRITION &HEALTH$6,199
P41 · FY2000 · RR